Arcus Biosciences, Inc. announced a private placement of 15,238,096 common shares at a price of $21 per share for the gross proceeds of $320,000,016 on January 29, 2024. The transaction will include participation from returning investor Gilead Sciences, Inc. for 33% stake.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
17.18 USD | -0.15% | +10.15% | -10.26% |
08/05 | Transcript : Arcus Biosciences, Inc., Q1 2024 Earnings Call, May 08, 2024 | |
08/05 | Earnings Flash (RCUS) ARCUS BIOSCIENCES Posts Q1 Revenue $145M | MT |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
67.7 USD | +0.23% | +3.35% | 8.41TCr | ||
17.18 USD | -0.15% | +10.15% | 156.53Cr | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-10.26% | 156.53Cr | |
+28.33% | 4.82TCr | |
-0.43% | 4.17TCr | |
+43.45% | 4.1TCr | |
-5.26% | 2.88TCr | |
+10.84% | 2.56TCr | |
-22.70% | 1.9TCr | |
+8.76% | 1.29TCr | |
+30.34% | 1.2TCr | |
-1.66% | 1.18TCr |
- Stock Market
- Equities
- RCUS Stock
- News Arcus Biosciences, Inc.
- Arcus Biosciences, Inc. announced that it expects to receive $320.000016 million in funding from Gilead Sciences, Inc.